



Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins – a single cohort 4-year follow-up study

| | |
|---------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID: | bmjopen-2011-000646.R3 |
| Article Type: | Research |
| Date Submitted by the Author: | 14-Jun-2012 |
| Complete List of Authors: | Hefter, Harald Hartmann, Christian Kahlen, Ulrike Moll, Marek Bigalke, Hans |
| Primary Subject Heading: | Neurology |
| Secondary Subject Heading: | Medical management, Pharmacology and therapeutics |
| Keywords: | secondary non-responder , cervical dystonia , cessation of therapy , neutralising antibody titre, complexing proteins , botulinum neurotoxin |
| | |

SCHOLARONE™
Manuscripts

1
2
3 **Prospective analysis of neutralising antibody titres in secondary non-responders**
4 **under continuous treatment with a botulinumtoxin type A preparation free of**
5 **complexing proteins – a single cohort 4-year follow-up study**
6
7
8
9

10
11
12 Harald Hefter¹, Christian Hartmann¹, Ulrike Kahlen¹, Marek Moll¹, Hans Bigalke²

13
14 ¹ Department of Neurology, University of Düsseldorf, Moorenstrasse 5, Düsseldorf, Germany

15
16 ² Institute of Toxicology, Medical School Hannover, Hannover, Germany
17
18
19

20
21 Corresponding author

22
23 Harald Hefter

24
25 Department of Neurology, University of Düsseldorf

26
27 Moorenstrasse 5, D-40225 Düsseldorf, Germany

28
29 Email: harald.hefter@online.de

30
31 Tel: +49 211 811 7025

32
33 Fax: +49 211 811 4903
34
35
36
37

38 I Harald Hefter the Corresponding Author of this article contained within the original
39 manuscript which includes any diagrams & photographs, other illustrative material, video,
40 film or any other material howsoever submitted by the Contributor(s) at any time and related
41 to the Contribution (“the Contribution”) have the right to grant on behalf of all authors and do
42 grant on behalf of all authors, a licence to the BMJ Publishing Group Ltd and its licensees, to
43 permit this Contribution (if accepted) to be published in BMJ Open and any other BMJ Group
44 products and to exploit all subsidiary rights, as set out in the licence at:
45
46
47
48
49
50
51
52

53 (http://group.bmj.com/products/journals/instructions-for-authors/BMJOpen_licence.pdf)
54
55
56
57
58
59
60

1
2
3 **Word count (text):** 1807

4 **Word count (abstract):** 296

5
6
7 **Tables/Figures:** 0/2

8
9 **References:** 18

10
11 **Short title:** Low antigenicity of incobotulinumtoxinA
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Objective. In long-term botulinum neurotoxin treatment, loss of therapeutic efficacy may occur due to neutralising antibody formation. Preliminary results with incobotulinumtoxinA, a preparation free of complexing / accessory proteins, have indicated a low antigenicity. We hypothesised that continuous treatment with this botulinum neurotoxin preparation would not result in an increase in neutralising antibody titres (NABTs) in patients with preexisting NABTs.

Design. Prospective, blinded cohort study.

Setting. Single centre in Germany.

Participants. Thirty-seven cervical dystonia patients with NABTs and partial secondary non-responsiveness to their previous botulinum neurotoxin type A treatment.

Intervention. 3-monthly intramuscular injections of incobotulinumtoxinA with a constant dose of 200 MU per injection during the first year; thereafter up to 500 MU for the next 36 months.

Outcome measures. Primary outcome measure: number of patients in whom NABTs declined below the initial titre after 48 months of incobotulinumtoxinA treatment or in whom titres had become negative within the 48 months. Secondary outcome measure: steepness of changes in NABT. NABTs were determined by mouse hemidiaphragm assay. Findings were compared to long-term data from 24 cervical dystonia patients who had developed NABTs and in whom treatment had been discontinued.

Results. Following a transient increase in the first 24 months under incobotulinumtoxinA treatment in some patients, NABTs declined well below the initial titre in the majority of patients. Test assay results were negative in most of the patients followed for more than 36 months. NABTs seemed to decline into the negative detection range as rapidly under incobotulinumtoxinA treatment as after cessation of botulinum neurotoxin therapy.

1
2
3 **Conclusions.** The reduction of neutralising antibody titres despite continuous treatment with
4 incobotulinumtoxinA indicates low antigenicity of incobotulinumtoxinA. This might have
5 implications on restrictions such as minimum injection intervals of ≥ 10 weeks currently in
6 place for maintaining successful long-term application of botulinum neurotoxin.
7
8
9
10

11
12
13
14 **Key words:** secondary non-responder - cervical dystonia - cessation of therapy - neutralising
15 antibody titre - complexing proteins – botulinum neurotoxin
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- Evaluation of antigenicity of incobotulinumtoxinA, a botulinum neurotoxin type A preparation free of complexing proteins for the treatment of cervical dystonia.

Key messages

- Secondary non-responders to conventional type A preparations showed a decline in neutralising antibody titres despite continuous treatment with incobotulinumtoxinA over a period of up to 50 months.
- Neutralising antibody titres seemed to decline into the negative detection range as rapidly under incobotulinumtoxinA treatment as after cessation of botulinumtoxin therapy.
- These results indicate low antigenicity of incobotulinumtoxinA.

Strengths and limitations of this study

- Up to date this study is the largest investigation of secondary non-responders with neutralising antibodies against botulinumtoxinA.
- The continuous treatment with incobotulinumtoxinA in secondary non-responders according to current knowledge of immunogenicity of botulinumtoxins should have resulted in boosting of antibody titres. Instead an unexpected decline of antibody titres was observed.
- This is an interesting finding despite the small sample size (n=37). Monocentric data have to be confirmed in multicentre studies.

INTRODUCTION

Intramuscular injections of botulinum neurotoxin (BoNT) have become the treatment of choice for the symptomatic treatment of focal dystonias;¹ a recent evidence-based assessment gave a Level A recommendation for the treatment of cervical dystonia (CD).² Therapeutic BoNT type A (BoNT/A) preparations usually consist of a high molecular weight complex containing the biologically active 150 kDa neurotoxin, non-toxic complexing / accessory proteins, and excipients.³ Repeated BoNT injections can trigger an immune response and can result in the formation of neutralising antibodies against the botulinum neurotoxin which might lead to non-responsiveness to treatment.⁴ To minimise this loss of therapeutic effect, it is recommended to avoid risk factors such as booster injections, the use of high doses, and short intervals of less than 10 to 12 weeks between injections.⁵ Thus, optimal BoNT injection management leads to therapy restrictions in order to avoid secondary non-response.

Current treatment recommendations reduce the frequency of secondary non-response to approx. 2% over a treatment period of 2 years in patients with cervical dystonia.⁶ However, a considerable percentage of patients would prefer shorter injection intervals and more individualised treatment.⁷ There is thus still a need for a BoNT preparation with an extremely low antigenicity to avoid therapy restrictions and meet patients' needs. The new BoNT/A preparation free of complexing proteins seems to be such a candidate.

IncobotulinumtoxinA (Xeomin®, NT 201, Merz Pharmaceuticals GmbH, Germany) treatment has not only been proven efficacious and well tolerated in patients with CD⁸⁻¹⁰ but preliminary results also indicate a low antigenicity.^{3,11-13} The present study was designed to support these hints of low antigenicity. We hypothesised that continuous treatment with incobotulinumtoxinA would not result in an increase in neutralising antibody titres (NABTs) in patients with preexisting NABTs. To test our hypothesis, we prospectively analysed NABTs in an immunologically critical subgroup of patients with NABTs and partial

1
2
3 secondary non-responsiveness who were switched from long-term treatment with other
4
5 botulinumtoxin A preparations to incobotulinumtoxinA treatment.
6
7
8

9 10 **METHODS**

11 Thirty-seven adult patients suffering from idiopathic cervical dystonia (CD) partly in
12
13 combination with other focal or generalised dystonia had been satisfactorily treated long-term
14
15 with the BoNT/A preparations abobotulinumtoxinA (Dysport®, Ipsen Ltd., Slough, UK) or
16
17 onabotulinumtoxinA (Botox®, Allergan Inc, Irvine, USA). They were included in this
18
19 prospective, blinded, monocentric study 1. when clinically secondary non-responsiveness
20
21 with systematic worsening of the severity of cervical dystonia occurred –severity was
22
23 measured by means of the objective TSUI score¹⁴ (12 weeks after injection) at three
24
25 consecutive injection visits over a period of at least 6 months despite increased BoNT/A
26
27 doses– and 2. when patients had given their informed consent to be switched to
28
29 incobotulinumtoxinA.
30
31
32

33 IncobotulinumtoxinA was administered as intramuscular injections of 200 MU without
34
35 electromyography guidance every 3 months according to their previous BoNT/A injection
36
37 protocols. IncobotulinumtoxinA doses were kept constant during the first year; thereafter,
38
39 doses could be adjusted according to the patients' requirements, reduced or increased up to
40
41 500 MU per injection.
42
43
44

45 The study was carried out according to the Declaration of Helsinki and Good Clinical
46
47 Practice.
48

49 Blood samples for BoNT antibody testing were collected at the start of the study and in yearly
50
51 intervals. Antibody titres were determined by an independent blinded contractor (Toxogen
52
53 GmbH, Hannover, Germany) using the sensitive mouse hemidiaphragm assay for neutralising
54
55 antibodies.¹⁵ Base10 logarithms are presented for all titres (\log_{10} (NABT) [mU/ml]); the value
56
57 of -1.3 was assigned to a negative test result. The upper limit of neutralising antibody
58
59
60

1
2
3 detection in the mouse hemidiaphragm assay was 10 mU/mL ($\log_{10}(10) = 1$), the lower limit
4 was 0.1 mU/ml ($(\log_{10}(0.1) = -1)$). The use of the logarithmic scale allows the comparison of
5 NABTs over the broad range of titres between 10 mU/ml and 0.1 mU/ml.
6
7

8
9 The primary outcome measure of the study was the number of patients in whom NABTs
10 declined below the initial titre after 48 months of incobotulinumtoxinA treatment or who had
11 negative titre results within the 48 months. The steepness of changes in NABT was chosen as
12 secondary outcome measure. This parameter turned out to be difficult to calculate, because
13 the titre had dropped below the detection limit in too many patients.
14
15
16
17
18
19

20
21 To test our hypothesis, the formation of neutralising antibodies in the present patient
22 population was followed over a period of up to 50 months.
23
24

25 The temporal course of neutralising antibody titres (NABTs) was compared to the course of
26 NABTs of 24 CD patients who had their BoNT treatment discontinued after development of
27 antibody-induced treatment failure. NABTs of eight of these 24 patients have been described
28 in the literature,¹⁶ the remaining 16 are follow-up patients from our centre.
29
30
31
32
33
34
35
36

37 For quantification of the slope of NABT decline, patient data were divided into three groups.
38 Group 1 included the titres of the 16 patients observed in our department with partial therapy
39 failure who had their BoNT treatment discontinued. Group 2 were the NABTs of the 8
40 patients with complete therapy failure reported in the literature¹⁶ and group 3 included the
41 titres of 37 patients with partial therapy failure who received continuous incobotulinumtoxinA
42 treatment after positive NABTs were detected. The decline in NABTs was quantified by
43 calculating a linear regression line through \log_{10} AB-titre values against time
44 ($\log_{10}(\text{mU/ml/year})$) for each patient. A negative titre was substituted by $\log_{10}(0.01)$, because
45 0.01 is the next titre value below the detection limit of 0.01 mU/ml.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 For group comparisons, an ANOVA was performed (Kruskal-Wallis test), for group mean
4 comparisons the non-parametric Mann-Whitney U test was used. These tests are part of the
5 commercially available statistics package SPSS.
6
7
8
9

10 11 RESULTS

12 The two figures show the temporal course of neutralising antibody titres over a period of up to
13 50 months in secondary non-responders who were either switched to incobotulinumtoxinA
14 (Figure 1), or did not receive any further BoNT treatment (Figure 2).
15
16
17
18
19

20 Antibody titre values of one of the CD patients with cessation of BoNT treatment (Figure 2)
21 were included for a visual marker in Figure 1 (symbol: black square, bold line). This patient
22 had high titres (upper limit of detection); after a slow decline over the first 30 months, the
23 neutralising antibody test was negative at the end of the 50-month observation period.
24
25
26
27
28

29 Despite a transient increase in 10 patients in the first 24 months under incobotulinumtoxinA
30 treatment (Figure 1), neutralising antibody titres declined well below the initial titre in the
31 majority of patients (31 patients, 84%, $p < 0.001$, chi-square test). Test assay results were even
32 negative or below the lower detection limit in 23 (62%) of the patients in the follow-up, i.e.
33 antibody titres were ≤ 0.1 mU/ml. In Figure 2 decline of titres is demonstrated for the patients
34 in whom therapy was stopped (light grey squares = published patients, coloured circles own
35 patients).
36
37
38
39
40
41
42
43
44

45 There was considerable inter-individual variability in the steepness of the titre decline in all
46 three patient populations (Figure 1 and 2). In most patients receiving incobotulinumtoxinA
47 treatment (Figure 1), baseline titres were lower than in the patients with discontinued
48 treatment (Figure 2). Under incobotulinumtoxinA treatment, antibody titres seemed to decline
49 into the negative detection range as rapidly as after cessation of therapy and in some cases
50 became negative even earlier than in those patients who had discontinued their BoNT/A
51 treatment, probably because of lower initial titres.
52
53
54
55
56
57
58
59
60

1
2
3 Mean slope of NABT decline ($-0.0516 \log_{10}(\text{mU/ml})/\text{year}$) was lowest in the patients with
4 partial therapy failure in whom BoNT treatment was discontinued after detection of positive
5 NABTs (group 1). Variability of slopes was also highest in this group (min: -0.2168 ; max:
6 0.0048 ; SD: 0.6463). The NABTs reported in the literature for patients with complete
7 treatment failure (group 2) declined rather homogeneously (-0.0664 ; min: -1.1620 ; max: $-$
8 0.0348 ; SD: 0.2897). However, the mean slope for group 2 did not differ significantly from
9 the mean slope for group 1 ($p=0.12$). The steepest mean slope of NABT decline (-0.0750) was
10 observed in group 3 (min: -0.9484 ; max: 0.1505 ; SD: 0.1725).

11 The Kruskal-Wallis test did not show any significant differences of slopes of NABT decline
12 between the groups ($p=0.269$). Even when groups 1 and 2 were combined and slopes of
13 patients with and without incobotulinumtoxinA treatment (group 3 vs. groups 1+2) were
14 compared, no significant difference could be detected ($p=0.816$).

34 DISCUSSION

35 IncobotulinumtoxinA is a preparation free of complexing proteins with a high specific
36 biological activity.^{3,17}

37 The patients included in our investigation had already developed secondary treatment failure
38 and neutralising antibodies under the former treatment with botulinum toxin type A
39 formulations containing complexing proteins. Despite their sensitivity to react to BoNT/A
40 treatment with antibody formation and despite a possible increase of doses up to 500 MU
41 incobotulinumtoxinA, more than 80% of these patients showed a decrease in antibody titres
42 and in more than 60% a reduction down to the detection limit was observed. The antigen load
43 of repetitive injections with 200 to 500 MU incobotulinumtoxinA every 3 months was
44 apparently so low that in this cohort of immunologically critical patients no permanent
45 boosting of antibody titres was observed. This confirms our hypothesis. We do not know
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 whether this occurs because the protein load of 0.88 ng to 2.2 ng (200 to 500 MU) of active
4 neurotoxin is not detected by the human immune system after intramuscular injections or
5 because of the lack of complexing proteins. The role of complexing proteins regarding the
6 efficacy of treatment in secondary non-responders with BoNT/A is still unclear but deserves
7 further interest.
8

9
10 Since NABTs under incobotulinumtoxinA treatment declined at least as rapidly as after
11 cessation of therapy, we recommend to detect antibody-induced therapy failure as early as
12 possible to avoid any further increase in NABTs and development of complete treatment
13 failure. Comparison of Figures 1 and 2 indicates the tendency that in patients with partial
14 therapy failure (group 1 and 3) titres return to negative values earlier than in patients with
15 complete therapy failure and higher antibody titres (group 2).
16

17
18 This is important for further continuation of BoNT/A treatment. It has been observed that in a
19 patient with antibody-induced therapy failure and negative antibody titres after cessation of
20 therapy after several years, no new formation of neutralising antibodies and clinical response
21 occurred when continuously high doses of incobotulinumtoxinA were injected in the
22 following years.¹⁸ Clinical response was also observed in the majority of our patients after
23 switching to incobotulinumtoxinA.¹³
24

25
26 The present paper does not only show that NABTs did not increase by incobotulinumtoxinA
27 treatment but we also present evidence that the decline in NABTs was not significantly
28 different in patients who were continuously treated with incobotulinumtoxinA following
29 partial therapy failure with other BoNT preparations compared to patients who no longer
30 received BoNT treatment after neutralising antibody titres were detected.
31

32
33 The present study has a potential impact on patient management. If it is confirmed in
34 additional studies that the antigenicity of incobotulinumtoxinA is as extremely low as
35 suggested here – it has to be kept in mind that the presented data were produced in an
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 uncontrolled, non-randomised study from a single centre— injection intervals and dosages can
4
5 possibly be modified to meet patients' need for an optimised individual treatment.
6
7

8
9
10 **Acknowledgments** Neutralising antibody assays were carried out by Toxogen GmbH,
11 Hannover, Germany. Editorial assistance was provided by Elke Grosselindemann (Brett
12 Medical Writing Australia).
13
14

15
16
17
18 **Funding** All costs associated with the publishing of the present manuscript were met by Merz
19 Pharmaceuticals GmbH, Frankfurt, Germany. Merz Pharmaceuticals also paid for the
20 neutralising antibody assays. Merz Pharmaceuticals was not involved in study design, data
21 collection, and data analysis and interpretation. The authors were independent from the
22 funder; they had full access to all presented data and take responsibility for all data and
23 analyses.
24
25
26
27
28
29
30
31

32
33
34 **Competing interest** HH: participated in research studies for which unrestricted grants were
35 provided by Allergan, Merz and Ipsen. He has been the recipient of honoraria and fees for
36 presentations at meetings and conferences and for participating in Advisory Boards from
37 Allergan, Ipsen and Merz; MM and UK: received honoraria and fees for presentations at
38 meetings and conferences; CH: nothing to declare; HB: is shareholder and CEO of Toxogen
39 GmbH, a spin-off of Medical School Hannover.
40
41
42
43
44
45
46
47
48

49 **Patient consent** Obtained.

50
51
52 **Ethics approval** The local ethics committee was asked and agreed on the continuation of
53 botulinumtoxin treatment with the new preparation, incobotulinumtoxinA, as a possible
54 treatment option. Usually the recommendation for secondary non-responders is to stop
55 botulinumtoxin treatment.
56
57
58
59
60

1
2
3 **Data sharing** There are no additional study data.
4

5 **Contributors** Study design, data collection, analysis and interpretation were carried out by all
6
7 authors. HH prepared the first draft of the manuscript; all authors participated in the final
8
9 preparation of the manuscript and approved the final version.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES


1. Jankovic J. Botulinum toxin in clinical practice. *J Neurol Neurosurg Psychiatry* 2004;75:951–7.
2. Simpson DM, Blitzer A, Brashear A, *et al.* Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2008;70:1699–706.
3. Frevert J. Content of botulinum neurotoxin in botox(r)/vistabel(r), disport(r)/azzalure(r), and xeomin(r)/bocouture(r). *Drugs R D* 2010;10:67–73.
4. Naumann M, Carruthers A, Carruthers J, *et al.* Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. *Mov Disord* 2010;25:2211–8.
5. Dressler D. Botulinum toxin drugs: future developments. *J Neural Transm* 2008;115:575–7.
6. Brin MF, Comella CL, Jankovic J, *et al.* Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. *Mov Disord* 2008;23:1353–60.
7. Fargel M, Psaila E. Results of a multi-national patient and physician survey on treatment satisfaction with current botulinum toxin treatment in focal dystonia. *Mov Disord* 2010; 25(Suppl.2):S511 (abstract 980).
8. Benecke R, Jost WH, Kanovsky P, *et al.* A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. *Neurology* 2005;64:1949–51.
9. Comella CL, Jankovic J, Truong DD, *et al.* Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. *J Neurol Sci* 2011;308:103-9.


- 1
2
3 10. Hanschmann A, Grafe S. Safety and efficacy of repeated NT 201 (botulinum
4
5 neurotoxin type A free from complexing proteins) injections of patients with cervical
6
7 dystonia: a first long-term safety analysis. *Mov Disord* 2010;25(Suppl.2):S237
8
9 (abstract 153).
- 10
11 11. Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins
12
13 (Xeomin®) in focal dystonia. *Drugs* 2007;67:669–83.
- 14
15 12. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or
16
17 a hindrance? *Biologics* 2010;4:325–32.
- 18
19 13. Hefter H, Kahlen U, Moll M, *et al.* Follow-up of neutralizing antibody titers after
20
21 continuous treatment with a BoNT/A preparation free from complexing proteins in
22
23 patients with dystonia and secondary non-response to other BoNT/A preparations. *J*
24
25 *Neurol Sci* 2009;285(S1): S299.
- 26
27 14. Tsui JK, Eisen A, Stoessl AJ, *et al.* Double-blind study of botulinum toxin in
28
29 spasmodic torticollis. *Lancet* 1986;2:245–7.
- 30
31 15. Göschel H, Wohlfarth K, Frevert J, *et al.* Botulinum A toxin therapy: neutralizing and
32
33 nonneutralizing antibodies – therapeutic consequences. *Exp Neurol* 1997;147:96–102.
- 34
35 16. Dressler D, Bigalke H. Botulinum toxin antibody type A titres after cessation of
36
37 botulinum toxin therapy. *Mov Disord* 2002;17:170–3.
- 38
39 17. Dressler D. Botulinum toxin for treatment of dystonia. *Eur J Neurol*
40
41 2010;17(Suppl.1):88–96.
- 42
43 18. Adib Saberi F, Bigalke H, Dressler D. Antigenicity differences between two brands of
44
45 botulinum toxin A. *Mov Disord* 2010; 25(Suppl.2):S227 (abstract 125).
- 46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1 Decline in neutralising antibody titres in 37 partial secondary non-responders (group 3) with cervical dystonia who were switched from their previous botulinum neurotoxin type A therapy to incobotulinumtoxinA treatment following the detection of neutralising antibodies. (coloured symbols ●, ▲, ×, ■, ◆) patients receiving incobotulinumtoxinA; (■, bold line) data from one patient with cessation of botulinum toxin therapy were included as visual marker for comparison with Figure 2. NABT, neutralising antibody titre

Figure 2 Decline in neutralising antibody titres in 24 patients with cervical dystonia after cessation of botulinum neurotoxin type A therapy following the detection of neutralising antibodies. (■) patients described in Dressler *et al.*¹⁶, group 2 with complete therapy failure; (coloured ●) follow-up patients from our centre, group 1 with partial therapy failure; data of one patient (■, bold line) were highlighted for comparison with Figure 1. Please note that titre changes can only be presented for the time span when titres were within the detection limits of the mouse hemidiaphragm assay. NABT, neutralising antibody titre





1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1
2
3 **Prospective analysis of neutralising antibody titres in secondary non-responders**
4 **under continuous treatment with a botulinumtoxin type A preparation free of**
5 **complexing proteins – a single cohort 4-year follow-up study**
6
7
8
9

10
11 Harald Hefter¹, Christian Hartmann¹, Ulrike Kahlen¹, Marek Moll¹, Hans Bigalke²

12
13
14 ¹ Department of Neurology, University of Düsseldorf, Moorenstrasse 5, Düsseldorf, Germany

15
16 ² Institute of Toxicology, Medical School Hannover, Hannover, Germany
17
18
19

20
21 Corresponding author

22
23 Harald Hefter

24
25 Department of Neurology, University of Düsseldorf

26
27 Moorenstrasse 5, D-40225 Düsseldorf, Germany

28
29 Email: harald.hefter@online.de

30
31 Tel: +49 211 811 7025

32
33 Fax: +49 211 811 4903
34
35
36
37

38 I Harald Hefter the Corresponding Author of this article contained within the original
39 manuscript which includes any diagrams & photographs, other illustrative material, video,
40 film or any other material howsoever submitted by the Contributor(s) at any time and related
41 to the Contribution (“the Contribution”) have the right to grant on behalf of all authors and do
42 grant on behalf of all authors, a licence to the BMJ Publishing Group Ltd and its licensees, to
43 permit this Contribution (if accepted) to be published in BMJ Open and any other BMJ Group
44 products and to exploit all subsidiary rights, as set out in the licence at:
45
46
47
48
49
50
51
52

53 (http://group.bmj.com/products/journals/instructions-for-authors/BMJOpen_licence.pdf)
54
55
56
57
58
59
60

1
2
3 **Word count (text):** 1807

4 **Word count (abstract):** 296

5
6
7 **Tables/Figures:** 0/2

8
9 **References:** 18

10
11 **Short title:** Low antigenicity of incobotulinumtoxinA
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Objective. In long-term botulinum neurotoxin treatment, loss of therapeutic efficacy may occur due to neutralising antibody formation. Preliminary results with incobotulinumtoxinA, a preparation free of complexing / accessory proteins, have indicated a low antigenicity. We hypothesised that continuous treatment with this botulinum neurotoxin preparation would not result in an increase in neutralising antibody titres (NABTs) in patients with preexisting NABTs.

Design. Prospective, blinded cohort study.

Setting. Single centre in Germany.

Participants. Thirty-seven cervical dystonia patients with NABTs and partial secondary non-responsiveness to their previous botulinum neurotoxin type A treatment.

Intervention. 3-monthly intramuscular injections of incobotulinumtoxinA with a constant dose of 200 MU per injection during the first year; thereafter up to 500 MU for the next 36 months.

Outcome measures. Primary outcome measure: number of patients in whom NABTs declined below the initial titre after 48 months of incobotulinumtoxinA treatment or in whom titres had become negative within the 48 months. Secondary outcome measure: steepness of changes in NABT. NABTs were determined by mouse hemidiaphragm assay. Findings were compared to long-term data from 24 cervical dystonia patients who had developed NABTs and in whom treatment had been discontinued.

Results. Following a transient increase in the first 24 months under incobotulinumtoxinA treatment in some patients, NABTs declined well below the initial titre in the majority of patients. Test assay results were negative in most of the patients followed for more than 36 months. NABTs seemed to decline into the negative detection range as rapidly under incobotulinumtoxinA treatment as after cessation of botulinum neurotoxin therapy.

1
2
3 **Conclusions.** The reduction of neutralising antibody titres despite continuous treatment with
4 incobotulinumtoxinA indicates low antigenicity of incobotulinumtoxinA. This might have
5 implications on restrictions such as minimum injection intervals of ≥ 10 weeks currently in
6 place for maintaining successful long-term application of botulinum neurotoxin.
7
8
9
10

11
12
13
14 **Key words:** secondary non-responder - cervical dystonia - cessation of therapy - neutralising
15 antibody titre - complexing proteins – botulinum neurotoxin
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- Evaluation of antigenicity of incobotulinumtoxinA, a botulinum neurotoxin type A preparation free of complexing proteins for the treatment of cervical dystonia.

Key messages

- Secondary non-responders to conventional type A preparations showed a decline in neutralising antibody titres despite continuous treatment with incobotulinumtoxinA over a period of up to 50 months.
- Neutralising antibody titres seemed to decline into the negative detection range as rapidly under incobotulinumtoxinA treatment as after cessation of botulinumtoxin therapy.
- These results indicate low antigenicity of incobotulinumtoxinA.

Strengths and limitations of this study

- Up to date this study is the largest investigation of secondary non-responders with neutralising antibodies against botulinumtoxinA.
- The continuous treatment with incobotulinumtoxinA in secondary non-responders according to current knowledge of immunogenicity of botulinumtoxins should have resulted in boosting of antibody titres. Instead an unexpected decline of antibody titres was observed.
- This is an interesting finding despite the small sample size (n=37). Monocentric data have to be confirmed in multicentre studies.

INTRODUCTION

Intramuscular injections of botulinum neurotoxin (BoNT) have become the treatment of choice for the symptomatic treatment of focal dystonias;¹ a recent evidence-based assessment gave a Level A recommendation for the treatment of cervical dystonia (CD).² Therapeutic BoNT type A (BoNT/A) preparations usually consist of a high molecular weight complex containing the biologically active 150 kDa neurotoxin, non-toxic complexing / accessory proteins, and excipients.³ Repeated BoNT injections can trigger an immune response and can result in the formation of neutralising antibodies against the botulinum neurotoxin which might lead to non-responsiveness to treatment.⁴ To minimise this loss of therapeutic effect, it is recommended to avoid risk factors such as booster injections, the use of high doses, and short intervals of less than 10 to 12 weeks between injections.⁵ Thus, optimal BoNT injection management leads to therapy restrictions in order to avoid secondary non-response.

Current treatment recommendations reduce the frequency of secondary non-response to approx. 2% over a treatment period of 2 years in patients with cervical dystonia.⁶ However, a considerable percentage of patients would prefer shorter injection intervals and more individualised treatment.⁷ There is thus still a need for a BoNT preparation with an extremely low antigenicity to avoid therapy restrictions and meet patients' needs. The new BoNT/A preparation free of complexing proteins seems to be such a candidate.

IncobotulinumtoxinA (Xeomin®, NT 201, Merz Pharmaceuticals GmbH, Germany) treatment has not only been proven efficacious and well tolerated in patients with CD⁸⁻¹⁰ but preliminary results also indicate a low antigenicity.^{3,11-13} The present study was designed to support these hints of low antigenicity. We hypothesised that continuous treatment with incobotulinumtoxinA would not result in an increase in neutralising antibody titres (NABTs) in patients with preexisting NABTs. To provetest our hypothesis, we prospectively analysed NABTs in an immunologically critical subgroup of patients with NABTs and partial

1
2
3 secondary non-responsiveness who were switched from long-term treatment with other
4
5 botulinumtoxin A preparations to incobotulinumtoxinA treatment.
6
7

8 9 10 **METHODS**

11 Thirty-seven adult patients suffering from idiopathic cervical dystonia (CD) partly in
12 combination with other focal or generalised dystonia had been satisfactorily treated long-term
13 with the BoNT/A preparations abobotulinumtoxinA (Dysport®, Ipsen Ltd., Slough, UK) or
14 onabotulinumtoxinA (Botox®, Allergan Inc, Irvine, USA). They were included in this
15 prospective, blinded, monocentric study 1. when clinically secondary non-responsiveness
16 with systematic worsening of the severity of cervical dystonia occurred –severity was
17 measured by means of the objective TSUI score¹⁴ (12 weeks after injection) at three
18 consecutive injection visits over a period of at least 6 months despite increased BoNT/A
19 doses– and 2. when patients had given their informed consent to be switched to
20 incobotulinumtoxinA.
21
22

23 IncobotulinumtoxinA was administered as intramuscular injections of 200 MU without
24 electromyography guidance every 3 months according to their previous BoNT/A injection
25 protocols. IncobotulinumtoxinA doses were kept constant during the first year; thereafter,
26 doses could be adjusted according to the patients' requirements, reduced or increased up to
27 500 MU per injection.
28
29

30 The study was carried out according to the Declaration of Helsinki and Good Clinical
31 Practice.
32
33

34 Blood samples for BoNT antibody testing were collected at the start of the study and in yearly
35 intervals. Antibody titres were determined by an independent blinded contractor (Toxogen
36 GmbH, Hannover, Germany) using the sensitive mouse hemidiaphragm assay for neutralising
37 antibodies.¹⁵ Base10 logarithms are presented for all titres (\log_{10} (NABT) [mU/ml]); the value
38 of -1.3 was assigned to a negative test result. The upper limit of neutralising antibody
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 detection in the mouse hemidiaphragm assay was 10 mU/mL ($\log_{10}(10) = 1$), the lower limit
4 was 0.1 mU/ml ($(\log_{10}(0.1) = -1)$). The use of the logarithmic scale allows the comparison of
5 NABTs over the broad range of titres between 10 mU/ml and 0.1 mU/ml.
6
7

8
9 The primary outcome measure of the study was the number of patients in whom NABTs
10 declined below the initial titre after 48 months of incobotulinumtoxinA treatment or who had
11 negative titre results within the 48 months. The steepness of changes in NABT was chosen as
12 secondary outcome measure. This parameter turned out to be difficult to calculate, because
13 the titre had dropped below the detection limit in too many patients.
14
15
16
17
18
19

20
21 To test our hypothesis, the formation of neutralising antibodies in the present patient
22 population was followed over a period of up to 50 months.
23
24

25 The temporal course of neutralising antibody titres (NABTs) was compared to the course of
26 NABTs of 24 CD patients who had their BoNT treatment discontinued after development of
27 antibody-induced treatment failure. NABTs of eight of these 24 patients have been described
28 in the literature,¹⁶ the remaining 16 are follow-up patients from our centre.
29
30
31
32
33
34
35
36

37 For quantification of the slope of NABT decline, patient data were divided into three groups.
38 Group 1 included the titres of the 16 patients observed in our department with partial therapy
39 failure who had their BoNT treatment discontinued. Group 2 were the NABTs of the 8
40 patients with complete therapy failure reported in the literature¹⁶ and group 3 included the
41 titres of 37 patients with partial therapy failure who received continuous incobotulinumtoxinA
42 treatment after positive NABTs were detected. The decline in NABTs was quantified by
43 calculating a linear regression line through \log_{10} AB-titre values against time
44 ($\log_{10}(\text{mU/ml/year})$) for each patient. A negative titre was substituted by $\log_{10}(0.01)$, because
45 0.01 is the next titre value below the detection limit of 0.01 mU/ml.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 For group comparisons, an ANOVA was performed (Kruskal-Wallis test), for group mean
4 comparisons the non-parametric Mann-Whitney U test was used. These tests are part of the
5 commercially available statistics package SPSS.
6
7
8
9

10 11 **RESULTS**

12 The two figures show the temporal course of neutralising antibody titres over a period of up to
13 50 months in secondary non-responders who were either switched to incobotulinumtoxinA
14 (Figure 1), or did not receive any further BoNT treatment (Figure 2).
15
16
17
18
19

20 Antibody titre values of one of the CD patients with cessation of BoNT treatment (Figure 2)
21 were included for a visual marker in Figure 1 (symbol: black square, bold line). This patient
22 had high titres (upper limit of detection); after a slow decline over the first 30 months, the
23 neutralising antibody test was negative at the end of the 50-month observation period.
24
25
26
27
28

29 Despite a transient increase in 10 patients in the first 24 months under incobotulinumtoxinA
30 treatment (Figure 1), neutralising antibody titres declined well below the initial titre in the
31 majority of patients (31 patients, 84%, $p < 0.001$, chi-square test). Test assay results were even
32 negative or below the lower detection limit in 23 (62%) of the patients in the follow-up, i.e.
33 antibody titres were ≤ 0.1 mU/ml. In Figure 2 decline of titres is demonstrated for the patients
34 in whom therapy was stopped (light grey squares = published patients, coloured circles own
35 patients).
36
37
38
39
40
41
42
43
44

45 There was considerable inter-individual variability in the steepness of the titre decline in all
46 three patient populations (Figure 1 and 2). In most patients receiving incobotulinumtoxinA
47 treatment (Figure 1), baseline titres were lower than in the patients with discontinued
48 treatment (Figure 2). Under incobotulinumtoxinA treatment, antibody titres seemed to decline
49 into the negative detection range as rapidly as after cessation of therapy and in some cases
50 became negative even earlier than in those patients who had discontinued their BoNT/A
51 treatment, probably because of lower initial titres.
52
53
54
55
56
57
58
59
60

1
2
3 Mean slope of NABT decline ($-0.0516 \log_{10}(\text{mU/ml})/\text{year}$) was lowest in the patients with
4 partial therapy failure in whom BoNT treatment was discontinued after detection of positive
5 NABTs (group 1). Variability of slopes was also highest in this group (min: -0.2168 ; max:
6 0.0048 ; SD: 0.6463). The NABTs reported in the literature for patients with complete
7 treatment failure (group 2) declined rather homogeneously (-0.0664 ; min: -1.1620 ; max: $-$
8 0.0348 ; SD: 0.2897). However, the mean slope for group 2 did not differ significantly from
9 the mean slope for group 1 ($p=0.12$). The steepest mean slope of NABT decline (-0.0750) was
10 observed in group 3 (min: -0.9484 ; max: 0.1505 ; SD: 0.1725).

11 The Kruskal-Wallis test did not show any significant differences of slopes of NABT decline
12 between the groups ($p=0.269$). Even when groups 1 and 2 were combined and slopes of
13 patients with and without incobotulinumtoxinA treatment (group 3 vs. groups 1+2) were
14 compared, no significant difference could be detected ($p=0.816$).

34 DISCUSSION

35 IncobotulinumtoxinA is a preparation free of complexing proteins with a high specific
36 biological activity.^{3,17}

37 The patients included in our investigation had already developed secondary treatment failure
38 and neutralising antibodies under the former treatment with botulinum toxin type A
39 formulations containing complexing proteins. Despite their sensitivity to react to BoNT/A
40 treatment with antibody formation and despite a possible increase of doses up to 500 MU
41 incobotulinumtoxinA, more than 80% of these patients showed a decrease in antibody titres
42 and in more than 60% a reduction down to the detection limit was observed. The antigen load
43 of repetitive injections with 200 to 500 MU incobotulinumtoxinA every 3 months was
44 apparently so low that in this cohort of immunologically critical patients no permanent
45 boosting of antibody titres was observed. This confirms our hypothesis. We do not know
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 whether this occurs because the protein load of 0.88 ng to 2.2 ng (200 to 500 MU) of active
4 neurotoxin is not detected by the human immune system after intramuscular injections or
5 because of the lack of complexing proteins. The role of complexing proteins regarding the
6 efficacy of treatment in secondary non-responders with BoNT/A is still unclear but deserves
7 further interest.
8

9
10
11 Since NABTs under incobotulinumtoxinA treatment declined at least as rapidly as after
12 cessation of therapy, we recommend to detect antibody-induced therapy failure as early as
13 possible to avoid any further increase in NABTs and development of complete treatment
14 failure. Comparison of Figures 1 and 2 indicates the tendency that in patients with partial
15 therapy failure (group 1 and 3) titres return to negative values earlier than in patients with
16 complete therapy failure and higher antibody titres (group 2).
17

18
19 This is important for further continuation of BoNT/A treatment. It has been observed that in a
20 patient with antibody-induced therapy failure and negative antibody titres after cessation of
21 therapy after several years, no new formation of neutralising antibodies and clinical response
22 occurred when continuously high doses of incobotulinumtoxinA were injected in the
23 following years.¹⁸ Clinical response was also observed in the majority of our patients after
24 switching to incobotulinumtoxinA.¹³
25

26
27 The present paper does not only show that NABTs did not increase by incobotulinumtoxinA
28 treatment but we also present evidence that the decline in NABTs was not significantly
29 different in patients who were continuously treated with incobotulinumtoxinA following
30 partial therapy failure with other BoNT preparations compared to patients who no longer
31 received BoNT treatment after neutralising antibody titres were detected.
32
33

34
35
36 The present study has an [potential](#) impact on patient management. If it is confirmed in
37 additional studies that the antigenicity of incobotulinumtoxinA is as extremely low as
38 suggested here – it has to be kept in mind that the presented data were produced in an
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 uncontrolled, non-randomised study from a single centre— injection intervals and dosages can
4
5 possibly be modified to meet patients' need for an optimised individual treatment.
6
7

8
9
10 **Acknowledgments** Neutralising antibody assays were carried out by Toxogen GmbH,
11 Hannover, Germany. Editorial assistance was provided by Elke Grosselindemann (Brett
12 Medical Writing Australia).
13
14

15
16
17
18 **Funding** All costs associated with the publishing of the present manuscript were met by Merz
19 Pharmaceuticals GmbH, Frankfurt, Germany. Merz Pharmaceuticals also paid for the
20 neutralising antibody assays. Merz Pharmaceuticals was not involved in study design, data
21 collection, and data analysis and interpretation. [The authors were independent from the](#)
22 [funder; they had full access to all presented data and take responsibility for all data and](#)
23 [analyses.](#)
24
25
26
27
28
29
30
31

32
33
34 **Competing interest** HH: participated in research studies for which unrestricted grants were
35 provided by Allergan, Merz and Ipsen. He has been the recipient of honoraria and fees for
36 presentations at meetings and conferences and for participating in Advisory Boards from
37 Allergan, Ipsen and Merz; MM and UK: received honoraria and fees for presentations at
38 meetings and conferences; CH: nothing to declare; HB: is shareholder and CEO of Toxogen
39 GmbH, a spin-off of Medical School Hannover.
40
41
42
43
44
45
46
47
48

49 **Patient consent** Obtained.

50
51
52 **Ethics approval** The local ethics committee was asked and agreed on the continuation of
53 botulinumtoxin treatment with the new preparation, incobotulinumtoxinA, as a possible
54 treatment option. Usually the recommendation for secondary non-responders is to stop
55 botulinumtoxin treatment.
56
57
58
59
60

1
2
3 **Data sharing** There are no additional study data.
4

5 **Contributors** Study design, data collection, analysis and interpretation were carried out by all
6
7 authors. HH prepared the first draft of the manuscript; all authors participated in the final
8
9 preparation of the manuscript and approved the final version.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES

1. Jankovic J. Botulinum toxin in clinical practice. *J Neurol Neurosurg Psychiatry* 2004;75:951–7.
2. Simpson DM, Blitzer A, Brashear A, *et al.* Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2008;70:1699–706.
3. Frevert J. Content of botulinum neurotoxin in botox(r)/vistabel(r), disport(r)/azzalure(r), and xeomin(r)/bocouture(r). *Drugs R D* 2010;10:67–73.
4. Naumann M, Carruthers A, Carruthers J, *et al.* Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. *Mov Disord* 2010;25:2211–8.
5. Dressler D. Botulinum toxin drugs: future developments. *J Neural Transm* 2008;115:575–7.
6. Brin MF, Comella CL, Jankovic J, *et al.* Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. *Mov Disord* 2008;23:1353–60.
7. Fargel M, Psaila E. Results of a multi-national patient and physician survey on treatment satisfaction with current botulinum toxin treatment in focal dystonia. *Mov Disord* 2010; 25(Suppl.2):S511 (abstract 980).
8. Benecke R, Jost WH, Kanovsky P, *et al.* A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. *Neurology* 2005;64:1949–51.
9. Comella CL, Jankovic J, Truong DD, *et al.* Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. *J Neurol Sci* 2011;308:103-9.

10. Hanschmann A, Grafe S. Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with cervical dystonia: a first long-term safety analysis. *Mov Disord* 2010;25(Suppl.2):S237 (abstract 153).
11. Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (Xeomin®) in focal dystonia. *Drugs* 2007;67:669–83.
12. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? *Biologics* 2010;4:325–32.
13. Hefter H, Kahlen U, Moll M, *et al.* Follow-up of neutralizing antibody titers after continuous treatment with a BoNT/A preparation free from complexing proteins in patients with dystonia and secondary non-response to other BoNT/A preparations. *J Neurol Sci* 2009;285(S1): S299.
14. Tsui JK, Eisen A, Stoessl AJ, *et al.* Double-blind study of botulinum toxin in spasmodic torticollis. *Lancet* 1986;2:245–7.
15. Göschel H, Wohlfarth K, Frevert J, *et al.* Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies – therapeutic consequences. *Exp Neurol* 1997;147:96–102.
16. Dressler D, Bigalke H. Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy. *Mov Disord* 2002;17:170–3.
17. Dressler D. Botulinum toxin for treatment of dystonia. *Eur J Neurol* 2010;17(Suppl.1):88–96.
18. Adib Saberi F, Bigalke H, Dressler D. Antigenicity differences between two brands of botulinum toxin A. *Mov Disord* 2010; 25(Suppl.2):S227 (abstract 125).

Figure legends

Figure 1 Decline in neutralising antibody titres in 37 partial secondary non-responders (group 3) with cervical dystonia who were switched from their previous botulinum neurotoxin type A therapy to incobotulinumtoxinA treatment following the detection of neutralising antibodies. (coloured symbols ●, ▲, ×, ■, ◆) patients receiving incobotulinumtoxinA; (■, bold line) data from one patient with cessation of botulinum toxin therapy were included as visual marker for comparison with Figure 2. NABT, neutralising antibody titre

Figure 2 Decline in neutralising antibody titres in 24 patients with cervical dystonia after cessation of botulinum neurotoxin type A therapy following the detection of neutralising antibodies. (■) patients described in Dressler *et al.*¹⁶, group 2 with complete therapy failure; (coloured ●) follow-up patients from our centre, group 1 with partial therapy failure; data of one patient (■, bold line) were highlighted for comparison with Figure 1. Please note that titre changes can only be presented for the time span when titres were within the detection limits of the mouse hemidiaphragm assay. NABT, neutralising antibody titre